Rapid regulation of P-glycoprotein at the blood-brain barrier by endothelin-1

被引:123
作者
Hartz, AMS
Bauer, B
Fricker, G
Miller, DS
机构
[1] NIEHS, Lab Pharmacol & Chem, NIH, Res Triangle Pk, NC 27709 USA
[2] Univ Heidelberg, Inst Pharm & Mol Biotechnol, Heidelberg, Germany
关键词
D O I
10.1124/mol.104.001503
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The ATP-driven xenobiotic transporter P-glycoprotein is a critical element of the blood-brain barrier. To study regulation of P-glycoprotein function, we measured specific transport [(3'-oxo-4-butenyl-4-methyl-threonine(1), (valine(2)) cyclosporin (PSC833)-sensitive] of the fluorescent cyclosporin A derivative [N-epsilon(4-nitrobenzofurazan-7-yl)-D-Lys(8)]-cyclosporin A (NBDL-CSA) into the lumens of isolated rat brain capillaries using confocal microscopy and quantitative image analysis. Luminal NBDL-CSA accumulation was rapidly and reversibly reduced in a concentration-dependent manner by 0.1 to 100 nM endothelin-1 (ET-1). In this concentration range, ET-1 did not affect junctional permeability. The ETB receptor agonist sarafotoxin 6c also reduced transport. An ETB receptor antagonist blocked effects of ET-1 and sarafotoxin 6c; an ETA receptor antagonist was without effect. Consistent with this, immunostaining and Western blotting showed expression of the ETB receptor in brain capillary membranes. NBDL-CSA transport was also reduced by sodium nitroprusside, a NO donor, and by phorbol ester, a protein kinase C (PKC) activator. Inhibition of NO synthase (NOS) or PKC abolished the ET-1 effects. Thus, ET-1, acting through an ETB receptor, NOS, and PKC rapidly and reversibly reduced transport mediated by P-glycoprotein at the blood-brain barrier.
引用
收藏
页码:387 / 394
页数:8
相关论文
共 32 条
[1]  
Brooks DP, 1998, CONT BIOMED, P223
[2]   Effects of MDR1 and MDR3 P-glycoproteins, MRP1, and BCRP/MXR/ABCP on the transport of 99mTc-Tetrofosmin [J].
Chen, WS ;
Luker, KE ;
Dahlheimer, JL ;
Pica, CM ;
Luker, GD ;
Piwnica-Worms, D .
BIOCHEMICAL PHARMACOLOGY, 2000, 60 (03) :413-426
[3]   Expression, up-regulation, and transport activity of the multidrug-resistance protein ABCG2 at the mouse blood-brain barrier [J].
Cisternino, S ;
Mercier, C ;
Bourasset, F ;
Roux, F ;
Scherrmann, JM .
CANCER RESEARCH, 2004, 64 (09) :3296-3301
[4]   Localisation of breast cancer resistance protein in microvessel endothelium of human brain [J].
Cooray, HC ;
Blackmore, CG ;
Maskell, L ;
Barrand, MA .
NEUROREPORT, 2002, 13 (16) :2059-2063
[5]   Puromycin selectively increases mdr1a expression in immortalized rat brain endothelial cell lines [J].
Demeuse, P ;
Fragner, P ;
Leroy-Noury, C ;
Mercier, C ;
Payen, L ;
Fardel, O ;
Couraud, PO ;
Roux, F .
JOURNAL OF NEUROCHEMISTRY, 2004, 88 (01) :23-31
[6]   HIV-I-induced production of endothelin-I in an in vitro model of the human blood-brain barrier [J].
Didier, N ;
Banks, WA ;
Créminon, C ;
Dereuddre-Bosquet, N ;
Mabondzo, A .
NEUROREPORT, 2002, 13 (09) :1179-1183
[7]   A new multidrug resistance protein at the blood-brain barrier [J].
Eisenblätter, T ;
Galla, HJ .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2002, 293 (04) :1273-1278
[8]   Alkylglycerol opening of the blood-brain barrier to small and large fluorescence markers in normal and C6 glioma-bearing rats and isolated rat brain capillaries [J].
Erdlenbruch, B ;
Alipour, M ;
Fricker, G ;
Miller, DS ;
Kugler, W ;
Eibl, H ;
Lakomek, M .
BRITISH JOURNAL OF PHARMACOLOGY, 2003, 140 (07) :1201-1210
[9]   Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo [J].
Fellner, S ;
Bauer, B ;
Miller, DS ;
Schaffrik, M ;
Fankhänel, M ;
Spruss, T ;
Bernhardt, G ;
Graeff, C ;
Färber, L ;
Gschaidmeier, H ;
Buschauer, A ;
Fricker, G .
JOURNAL OF CLINICAL INVESTIGATION, 2002, 110 (09) :1309-1318
[10]   Downregulation of mdr1a expression in the brain and liver during CNS inflammation alters the in vivo disposition of digoxin [J].
Goralski, KB ;
Hartmann, G ;
Piquette-Miller, M ;
Renton, KW .
BRITISH JOURNAL OF PHARMACOLOGY, 2003, 139 (01) :35-48